Recent advances on blinatumomab for acute lymphoblastic leukemia
Abstract Although complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine kinase inhibitors, antibody–drug conjugates and chimeric antigen receptor T cell th...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2019-11-01
|
| coleção: | Experimental Hematology & Oncology |
| Assuntos: | |
| Acesso em linha: | http://link.springer.com/article/10.1186/s40164-019-0152-y |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|